Cancer Treatment Reviews

Article	Citations
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review	228
Editorial Board	220
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)	208
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty	203
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives	152
De-escalating adjuvant therapies in older patients with lower risk estrogen receptor-positive breast cancer treated with breast-conserving surgery: A systematic review and meta-analysis	132
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials	126
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas	120
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer	111
Systemic therapy for older patients with early breast cancer	108
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer	99
Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis	92
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer	85
Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group	80
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in	78
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?	77
Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications	75
Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis	75
Surgical tumor volume reduction in patients with brain metastases: A systematic review and meta-analysis	72
De-escalation strategies with targeted therapies in non-small cell lung cancer	68
FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma	68
Editorial Board	66
Emerging antibody-based therapies for the treatment of acute myeloid leukemia	65
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev.	62
First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features	60

If it’s a target, it’s a pan-cancer target: Tissue is not the issue	60
Optimizing care in early phase cancer trials: The role of palliative care	59
Uncertainties and controversies in axillary management of patients with breast cancer	58
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches	58
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis	58
Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges	54
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?	53
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials	53
Editorial Board	50
Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment	49
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck	48
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes	47
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC	46
Roadmap to cure multiple myeloma	46
Editorial Board	44
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations	44
Extracellular vesicles and the “six Rs” in radiotherapy	43
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review	43
Managing strategies of chemotherapy and radiotherapy-induced oral mucositis	42
Overview of BH3 mimetics in ovarian cancer	42
The immunogram of inflammatory breast cancer	41
Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: A systematic review and meta-analysis	41
Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design	41
Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada	40
Deciphering primary acinic cell carcinoma of the Breast: Insights from a comprehensive case series and Systematic review	40
Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma	40
HER-2 directed therapies across gastrointestinal tract cancers – A new frontier	40
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside	39
Optimizing outcomes and personalizing care with targeted agents in advanced cholangiocarcinoma	38
De-escalation of axillary irradiation for early breast cancer – Has the time come?	38
Long-term surveillance recommendations for young adult cancer survivors	37
The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives	36
Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities	36
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)	36
Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis	36
Immunocytokines in cancer treatment: A systematic review	35
Editorial Board	35
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features	35
Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies	34
European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer	34
Bone complications of cancer treatment	34
Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer	34
Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review	32
Agnostic drug development revisited	32
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer	31
Editorial Board	31
Malignant ascites: Current therapy options and treatment prospects	31
Acknowledgement to Reviewers 2021	31
Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)	31
Systematic review of the CUP trials characteristics and perspectives for next-generation studies	31

Editorial Board	30
Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review	30
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?	29
Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review	29
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers	28
Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes	28
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review	28
Local control strategies for management of NSCLC with oligoprogressive disease	27
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review	27
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis	27
Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification	27
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications	27
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?	26
Review: Targeting EZH2 in neuroblastoma	26
Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312]	26
Pharmacotherapy for leptomeningeal disease in breast cancer	26
Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic revie	26
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges	26
Strategies for improving detection of circulating tumor DNA using next generation sequencing	25
Engineering strategies to optimise adoptive cell therapy in ovarian cancer	25
Chemotherapy in pancreatic ductal adenocarcinoma: When cytoreduction is the aim. A systematic review and meta-analysis	25
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project	24
Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives	24
Evolving immunotherapeutic solutions for triple-negative breast carcinoma	24
Patient-reported outcome measure to implement routine assessment of cancer survivors’ unmet needs: An overview of reviews and COSMIN analysis	24
PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence	23
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer	23
KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond	23
Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS – GROUP). Part I	23
Editorial Board	22
Selecting systemic treatment for metastatic neuroendocrine tumors of the lung—current evidence and clinical implications	22
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis	22
Editorial Board	22
Identification of the PROMs used to assess ICI toxicities and HRQoL in patients receiving immune checkpoint inhibitor treatment in cancer care and their suitability: A systematic review	21
Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progression	21
Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis	21
Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis	21
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors	20
Challenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases	20
Editorial Board	20
Editorial Board	20
Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies	20
Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature	20
Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment	20
SELNET clinical practice guidelines for soft tissue sarcoma and GIST	20
Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives	20
Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review	20
Editorial Board	20
Considerations regarding a network meta-analysis of targeted therapies for BRAF-mutant unresectable or metastatic melanoma	20
Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis	19
From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia	19
A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments	19
A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors	19
Management approaches for recurrent or metastatic head and neck squamous cell carcinoma after anti-PD-1/PD-L1 immunotherapy	19
Multimodality treatment of primary cardiac angiosarcoma: A systematic literature review	19
Corrigendum to “Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)” [Cancer Treatment Reviews 123 (2024) 102672]	19
Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)	18
Challenges to genetic testing for germline mutations associated with breast cancer among African Americans	18
A systematic review of eHealth technologies for breast cancer supportive care	18
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines	18
Targeting HER2 heterogeneity in breast cancer	18
Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma	18
Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?	17
Desmoid-type fibromatosis: Current therapeutic strategies and future perspectives	17
Systematic review of real-world studies evaluating the impact of medication non-adherence to endocrine therapies on hard clinical endpoints in patients with non-metastatic breast cancer	17
Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis	17
Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives	17
Comparative review of KEYNOTE-689 and NIVOPOSTOP trials and their impact on perioperative immunotherapy in locally advanced head and neck cancer	17
Clearer Horizons: The latest advances in clear cell ovarian cancer treatment	17
Corrigendum to “PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives” [Cancer Treat. Rev. 131 (2024) 102850]	17
Clinical recommendations for treatment of localized angiosarcoma: A consensus paper by the Italian Sarcoma Group	17
MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action	17
Antibody-drug conjugates for hepato-pancreato-biliary malignancies: “Magic bullets” to the rescue?	17
First-line treatment of locally advanced cervical carcinoma: An updated systematic review and Bayesian network meta-analysis	17
Functioning neuroendocrine tumors (NET): Minimum requirements for a NET specialist	16
BRAFV600E mutant metastatic colorectal cancer: Current advances in personalized treatment and future perspectives	16
CAR-T cell therapy for breast cancer: Current status and future perspective	16
Corrigendum to “Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC” [Cancer Treat. Rev. 104 (2022) 102350]	16
T-cell engager toxicity in clinical phase trials; A systematic review and meta-analysis	16
Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospective studies	16

PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer	16
Exercise in patients with metastatic prostate cancer: A comprehensive review	16
Local administration of immunotherapy for patients with skin cancer: A systematic review	16
Current controversies in the use of Oncotype DX in early breast cancer	15
Treatment decision-making factors and sequencing in recurrent and/or metastatic squamous cell carcinoma of the head and neck	15
Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis	15
Individualizing first-line treatment for advanced urothelial carcinoma: A favorable dilemma for patients and physicians	15
The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review	15
Germline TP53 pathogenic variants and breast cancer: A narrative review	15
Editorial Board	15
Editorial Board	14
The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practice	14
Chimeric antigen receptor NK cells for breast cancer immunotherapy	14
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management	14
Editorial Board	14
Acquired resistance mechanisms to osimertinib: The constant battle	14
Antibody based therapies in Hodgkin lymphoma	13
Beyond HER2: Targeting the ErbB receptor family in breast cancer	13
The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer	13
Editorial Board	13
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing	13
Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer	13
Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations	13
Enhancing radiotherapy techniques for Triple-Negative breast cancer treatment	13
Editorial Board	13
Systematic review of fetal and placental metastases among pregnant patients with cancer	13
First line treatment of BRAF mutated advanced melanoma: Does one size fit all?	13
Advancements in platinum chemotherapy for metastatic castration-resistant prostate cancer: Insights and perspectives	12
Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news	12
Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development	12
European expert panel consensus on the clinical management of BRAF-mutant metastatic colorectal cancer	12
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy	12
Editorial Board	12
Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer	12
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?	12
Molecular aspects of brain metastases in breast cancer	12
The current clinical landscape of personalized cancer vaccines	12
Primary mediastinal large B-cell Lymphoma: Biological features, clinical characteristics and current treatment strategies	11
Editorial Board	11
Evasion of apoptosis and treatment resistance in squamous cell carcinoma of the head and neck	11
Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors	11
Immunotherapy-based combinations in metastatic NSCLC	11
Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review	11
Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma	11
Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis	11
Intermittent fasting and its impact on toxicities, symptoms and quality of life in patients on active cancer treatment	11
Response to “Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into ac	11
Editorial Board	11
Induction chemotherapy followed by chemoradiotherapy for locally advanced cervical cancer: A systematic review and meta-analysis	11
Corrigendum to “Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis” [Cancer Treat. Rev. 125 (2024) 102704]	11
Long road towards effective HER3 targeting in breast cancer	10
Implications of bone metastasis on response to systemic therapy in patients with advanced renal cell carcinoma: A systematic literature review	10
Opportunities and challenges in combining immunotherapy and radiotherapy in head and neck cancers	10
Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours	10
Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation	10
Editorial Board	10
Treatment of unresectable stage III non-small cell lung cancer for patients who are under-represented in clinical trials	10
Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges	10
Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma	10
Evolving therapeutics and ensuing cardiotoxicities in triple-negative breast cancer	10
Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review	10
Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma	9
Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists	9
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer	9
The 5-WS of targeting DNA-damage repair (DDR) pathways in prostate cancer	9
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials	9
Pleural mesothelioma (PM) – The status of systemic therapy	9
Pathologic complete response in patients with localized soft tissue sarcoma treated with neoadjuvant therapy and its correlation with clinical outcomes: A systematic review	9
Shaping the tumor immune microenvironment of SCLC: Mechanisms, and opportunities for immunotherapy	9
Toxicities following CAR-T therapy for hematological malignancies	9
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treat. Rev.	9
Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge	9
Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis	9
First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States	9
The present and the future of immunotherapy in hepatocellular carcinoma and biliary tract cancers	9
Systematic literature review of intravenous versus subcutaneous administration of oncology therapies: A clinical, economic and patient perspective	9
Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome	9
Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations. Spanish Group for Sarcoma research (GEIS –GROUP). Part II	8
Long and short-term efficacy and safety comparison of nab-paclitaxel versus paclitaxel combined with trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer: A systematic r	8
Comparative analysis of international guidelines on the management of advanced non-functioning well-differentiated pancreatic neuroendocrine tumors	8
Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis	8
The gut wall’s potential as a partner for precision oncology in immune checkpoint treatment	8
Oncological outcomes of local excision versus radical surgery for early rectal cancer in the context of staging and surveillance: A systematic review and meta-analysis	8
Compliance to chemoradiation in squamous cell carcinoma of the anus	8
NTRK gene fusion testing and management in lung cancer	8
Advances and challenges in immunotherapy for locally advanced nasopharyngeal carcinoma	8
Editorial Board	8
Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies	8
Should temozolomide be used on the basis of O6-methylguanine DNA methyltransferase status in patients with advanced neuroendocrine tumors? A systematic review and meta-analysis	8
How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force	8
Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon	8
Evolution of the HIF targeted therapy in clear cell renal cell carcinoma	8
Artificial intelligence for prediction of treatment outcomes in breast cancer: Systematic review of design, reporting standards, and bias	8
Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing	8
Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors	8